IMNM

Immunome, Inc. is a biotechnology company developing targeted cancer therapies using its proprietary antibody discovery platform. The company's technology enables the identification of novel antibody targets from patients who have naturally mounted an immune response to their cancer. Immunome's pipeline includes multiple antibody-drug conjugates and bispecific antibodies in various stages of development. The company focuses on solid tumors where conventional therapies have shown limited efficacy. Immunome's patient-driven discovery approach offers a differentiated strategy in oncology drug development.